High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study

Sari Riihuarvi; Heidi Nyman; Harald Holte; Magnus Bjorkholm; Oystein Fluge; Lars Moller Pedersen; Mats Jerkeman; Mikael Eriksson; Sirpa Leppa

High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study

Sari Riihuarvi, Heidi Nyman, Harald Holte, Magnus Bjorkholm, Oystein Fluge, Lars Moller Pedersen, Mats Jerkeman, Mikael Eriksson, Sirpa Leppa

Bröstcancer-genetik

Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract › Peer review

Originalspråk	engelska
Sidor (från-till)	1686-1686
Tidskrift	Blood
Volym	116
Nummer	21
Status	Published - 2010
Evenemang	52nd Annual Meeting of the American-Society-of-Hematology (ASH) - Orlando, FL Varaktighet: 2010 dec. 4 → 2010 dec. 7

Ämnesklassifikation (UKÄ)

Hematologi

Citera det här

Riihuarvi, S., Nyman, H., Holte, H., Bjorkholm, M., Fluge, O., Pedersen, L. M., Jerkeman, M., Eriksson, M., & Leppa, S. (2010). High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study. Blood, 116(21), 1686-1686.

@article{e17554be75c64343aee3a0be5553c143,

title = "High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study",

author = "Sari Riihuarvi and Heidi Nyman and Harald Holte and Magnus Bjorkholm and Oystein Fluge and Pedersen, {Lars Moller} and Mats Jerkeman and Mikael Eriksson and Sirpa Leppa",

year = "2010",

language = "English",

volume = "116",

pages = "1686--1686",

journal = "Blood",

issn = "1528-0020",

publisher = "American Society of Hematology",

number = "21",

note = "52nd Annual Meeting of the American-Society-of-Hematology (ASH) ; Conference date: 04-12-2010 Through 07-12-2010",

}

Riihuarvi, S, Nyman, H, Holte, H, Bjorkholm, M, Fluge, O, Pedersen, LM, Jerkeman, M , Eriksson, M & Leppa, S 2010, 'High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study', Blood, vol. 116, nr. 21, s. 1686-1686.

High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study. / Riihuarvi, Sari; Nyman, Heidi; Holte, Harald et al.
I: Blood, Vol. 116, Nr. 21, 2010, s. 1686-1686.

Forskningsoutput: Tidskriftsbidrag › Publicerat konferensabstract › Peer review

TY - JOUR

T1 - High Serum Vascular Endothelial Growth Factor (VEGF) Level Is An Adverse Prognostic Factor In High Risk Diffuse Large B Cell Lymphoma (DLBCL) Patients Treated with Dose Dense Chemoimmunotherapy and Systemic CNS Prophylaxis Results From a Nordic Phase II Study

AU - Riihuarvi, Sari

AU - Nyman, Heidi

AU - Holte, Harald

AU - Bjorkholm, Magnus

AU - Fluge, Oystein

AU - Pedersen, Lars Moller

AU - Jerkeman, Mats

AU - Eriksson, Mikael

AU - Leppa, Sirpa

PY - 2010

Y1 - 2010

M3 - Published meeting abstract

SN - 1528-0020

VL - 116

SP - 1686

EP - 1686

JO - Blood

JF - Blood

IS - 21

T2 - 52nd Annual Meeting of the American-Society-of-Hematology (ASH)

Y2 - 4 December 2010 through 7 December 2010

ER -